Last update: July 6, 2018

Olopatadine Hydrochloride

Very Low Risk for breastfeeding


Safe. Compatible.
Not risky for breastfeeding or infant.

An antihistamine and inhibitor of the release of proinflammatory mediators from mast cells.
Indicated in conjunctivitis and allergic rhinitis.
Topical administration, twice a day.

Since the date of last update, we have not found published data on its excretion in breastmilk.

As in most topical ophthalmological and nasal preparations, the minute dose and its negligible transfer into blood makes it compatible with breastfeeding.
Ophthalmic administration results in plasma concentrations that are very low or below the limit of quantification (EMA 2017, Meier 2017), which makes the transfer in significant amounts to breastmilk very unlikely.
Nasal absorption is greater, similar to oral absorption (57% bioavailability) (Chu 2009).

There are no cumulative effects after multiple doses (Meier 2017, Chu 2009) and side effects are not frequent or serious (EMA 2017).

In ophthalmic administration, absorption can be minimized by pressing a finger on the tear duct (medial canthus of the eye) for 1 minute.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Olopatadine Hydrochloride in other languages or writings:

Tradenames

Main tradenames from several countries containing Olopatadine Hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Oft <1, Nasal 57 %
Molecular weight 374 daltons
Protein Binding 55 %
VD 1,9 l/Kg
Tmax 1 - 2 hours
T1/2 2,9 - 3,4 hours

References

  1. EMA. Olopatadine (Opatanol). Drug Summary. 2017 Full text (in our servers)
  2. EMA. Olopatadina (Opatanol). Ficha técnica. 2017 Full text (in our servers)
  3. Meier E, Narvekar A, Iyer GR, DuBiner HB, Vutikullird A, Wirta D, Sall K. Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies. Clin Ophthalmol. 2017 Abstract
  4. Chu NN, Chen WL, Xu HR, Li XN. Pharmacokinetics of orally administered single- and multiple-dose olopatadine in healthy Chinese subjects: an open-label study. Clin Drug Investig. 2009 Abstract

Total visits

7,468

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM